Division of Orthopaedic Surgery News & Announcements

This week’s In The News highlights studies on influenza, antibiotic use, and e-scooter accidents.

The American Society for Bone and Mineral Research honored Dr. Fanxin Long for his signification contributions to the field.

The new Center for Outcomes Research in Surgery provides a patient-centered approach to improving outcomes in children with surgical conditions.

The FDA approved an oral drug, based on foundational research conducted at CHOP, to treat a rare, severe bone disease. More In The News.

Research from the Minds Matter Concussion Program at CHOP influenced new, international guidelines for the diagnosis, management, and prevention of concussion in sport.

Learn about novel findings from our Children’s Hospital of Philadelphia researchers.

Identified by CHOP researchers, palovarotene is the first drug approved (in Canada) for fibrodysplasia ossificans progressiva, a severe bone disease.

Palovarotene is the first approved drug against fibrodysplasia ossificans progressiva (FOP), a rare and often fatal disease.

This week’s In the News features new study on measuring vision changes in patients with neurofibromatosis type 1, and other research highlights.

CHOP researchers identified the drug, palovarotene, to treat fibrodysplasia ossificans progressive (FOP).

CHOP and its individual departments ranked high in U.S. News and World Report’s Best Children’s Hospitals for 2021-2022.

The February Featured Research Trainee, Kaylia Duncan, reflects on Black History Month and her scientific career.